Granting Authorization to Key Managerial Personnel for Determination of Materiality of Events.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Ltd reported FY2026 results with revenue from operations growing 16.6% to Rs. 77,165.74 Lakhs from Rs. 66,151.49 Lakhs in FY2025. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs (vs Rs. 4,735.19 Lakhs), and EBITDA margin compressed from 10.64% to 8.56%. The company posted negative operating cash flow of Rs. 301.16 Lakhs (vs positive Rs. 3,712.47 Lakhs in FY2025), primarily due to a significant Rs. 7,327.41 Lakhs increase in inventories. The board recommended a dividend of Rs. 1.50 per share (30% payout) and approved a 1:1 bonus share issuance from July 2025. Nine promoter group shareholders (totaling 0.95% stake) have sought re-classification to public category. The statutory auditor issued an unmodified (clean) opinion.
Revenue growth is positive but profitability declined with compressed margins and negative operating cash flow, which may concern investors focused on earnings quality. The dividend and bonus issuance provide some shareholder returns, but the cash flow deterioration warrants attention.